tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Mastrobuoni S et al. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience. 2007 Transplant. Proc. pmid:17889125
Diekmann F et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. 2001 Nov-Dec Transplant. Proc. pmid:11750386
van Duijnhoven E et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. 1998 Transplant. Proc. pmid:9636514
Balda S et al. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. 2009 Jul-Aug Transplant. Proc. pmid:19715841
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Morris R Modes of action of FK506, cyclosporin A, and rapamycin. 1994 Transplant. Proc. pmid:7527964
Khalaf H et al. Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity. 2003 Transplant. Proc. pmid:14612120
Celli S et al. Long-term survival of heart and liver xenografts with splenectomy and FK 506. 1993 Transplant. Proc. pmid:7679830
Tanabe K et al. ABO-incompatible living donor kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119903
Japanese study of FK 506 on kidney transplantation: results of late phase II study. 1993 Transplant. Proc. pmid:7679831
Beysens AJ et al. FK 506: monitoring in plasma or in whole blood? 1991 Transplant. Proc. pmid:1721263
Grenier FC et al. A whole blood FK 506 assay for the IMx analyzer. 1991 Transplant. Proc. pmid:1721264
Hashikura Y et al. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation. 1996 Transplant. Proc. pmid:8623218
Tomikawa S et al. Immunosuppressive effects of bactobolamine in vitro and in vivo. 1996 Transplant. Proc. pmid:8623223
Waller JR et al. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. 2005 Jan-Feb Transplant. Proc. pmid:15808582
Berman M et al. Lipid metabolism and immunosuppressive therapy in heart transplant recipients. 2003 Transplant. Proc. pmid:12644091
Lauzurica R et al. Monotherapy with tacrolimus and corticosteroid withdrawal. 2002 Transplant. Proc. pmid:11959217
Bilbao I et al. Experience with neoral cyclosporine through the oral route in liver transplantation. 1998 Transplant. Proc. pmid:9636580
Jang HJ et al. Comparison of pancreas transplantation outcome between the cyclosporine and tacrolimus eras. 2000 Transplant. Proc. pmid:11120249
San Segundo D et al. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. 2012 Transplant. Proc. pmid:23146491
Squifflet JP et al. The Benelux experience with the combination of tacrolimus and mycophenolate mofetil. 1999 Transplant. Proc. pmid:10576050
Watarai Y et al. Effect of tacrolimus and cyclosporine on renal microcirculation and nitric oxide production. 2004 Transplant. Proc. pmid:15518773
Sigal NH et al. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? 1991 Transplant. Proc. pmid:1721295
Tanabe K et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. 2004 Transplant. Proc. pmid:15518791
Nicoluzzi J et al. One hundred pancreas transplants performed in a Brazilian institution. 2009 Transplant. Proc. pmid:20005382
Tai HC et al. Urachal adenocarcinoma following kidney transplantation: the first case report. 2009 Transplant. Proc. pmid:19545760
Telkes G et al. Kidney transplantation in hereditary coproporphyria using tacrolimus and mycophenolate mofetil: a case report. 2013 Transplant. Proc. pmid:24315002
Okamoto M et al. Detection of allograft rejection in rat small bowel transplantation by analysing the in situ distribution of S-phase lymphocytes. 1994 Transplant. Proc. pmid:7518145
González-Pinto IM et al. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. 2005 Transplant. Proc. pmid:15919441
Ippoliti G et al. Serum cytokine levels after small bowel transplantation in pigs. 1994 Transplant. Proc. pmid:7518146
Wojewodzka J et al. Inhibition of formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction by cyclosporine and tacrolimus. 2003 Transplant. Proc. pmid:14529947
Barkholt LM et al. New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. 1995 Transplant. Proc. pmid:7533375
Chiang Y et al. Posttransplantation Kaposi sarcoma-experience in a patient receiving FK-506 and MMF. 2003 Transplant. Proc. pmid:12591389
Ogasa N et al. Successful transplantation of newborn rat intestine as a free graft. 1992 Transplant. Proc. pmid:1376514
Teraoka S et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. 1995 Transplant. Proc. pmid:7533381
Suga A et al. Diabetes mellitus after renal transplantation under tacrolimus-based immunosuppression. 2003 Transplant. Proc. pmid:12591391
Hesselink DA et al. The use of cyclosporine in renal transplantation. 2004 Transplant. Proc. pmid:15041316
Hultsch T and Hohman RJ Categorizing receptor-signaling pathways with FK 506 and rapamycin. 1991 Transplant. Proc. pmid:1721328
Figueras J et al. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. 2002 Transplant. Proc. pmid:12176461
Kahan BD Current approaches to the use of sirolimus in renal transplantation. 2009 Transplant. Proc. pmid:19857664
Soin AS et al. Complement activation during rejection in experimental intestinal transplantation. 1997 Transplant. Proc. pmid:9142282
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Hohage H et al. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study. 2005 Transplant. Proc. pmid:15919497
Ochiai T et al. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533435
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. 1991 Transplant. Proc. pmid:1721359
Strassburg A et al. Basiliximab reduces acute liver allograft rejection in pediatric patients. 2002 Transplant. Proc. pmid:12270443
Armitage JM et al. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. 1991 Transplant. Proc. pmid:1703336
Weimer R et al. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. 2002 Transplant. Proc. pmid:12270445
Kilinç M et al. FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report. 2002 Transplant. Proc. pmid:12072309
Fahlke J et al. Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study. 2002 Transplant. Proc. pmid:12072328
Uchida K et al. Excellent 3-year results following living-donor kidney transplantation and tacrolimus immunosuppression in Japan. 2002 Transplant. Proc. pmid:12176503
Malaise J et al. Tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: the EURO-SPK 3-year results. 2005 Jul-Aug Transplant. Proc. pmid:16182828
Goh BL et al. FK506 rescue therapy for acute renal allograft rejection. 1998 Transplant. Proc. pmid:9838574
Melk A et al. P-glycoprotein expression in patients before and after kidney transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083115
Zegarska J et al. Evaluation of the Relationship Between Concentrations of Tacrolimus Metabolites, 13-O-Demethyl Tacrolimus and 15-O-Demethyl Tacrolimus, and Clinical and Biochemical Parameters in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30177142
Katoh H et al. Effectiveness of 15-deoxyspergualin on steroid-resistant acute rejection in living related liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123125
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Rilo HL et al. Effect of FK 506 on function of human islets of Langerhans. 1991 Transplant. Proc. pmid:1721393
Tsuchiya T et al. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310593
Hatakeyama S et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310594
Braun F et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. 2001 Transplant. Proc. pmid:11377473
Saito K et al. Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. 2002 Transplant. Proc. pmid:12176553
Wierzbicka A et al. Lipid, carbohydrate metabolism, and antioxidant status in children after liver transplantation. 2007 Transplant. Proc. pmid:17580179
Mori T et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. 2007 Transplant. Proc. pmid:17580201
Zanker B et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083521
Mohamed MA et al. The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. 1999 Feb-Mar Transplant. Proc. pmid:10083523
Yu X et al. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation. 2008 Transplant. Proc. pmid:19100412
Yamagami S et al. Rejection mechanism and immunosuppression by FK 506 and anti-leukocyte function associated antigen-1 antibody in concordant corneal xenotransplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123598
Alkhunaizi AM et al. Breast fibroadenomas in renal transplant recipients. 2004 Jul-Aug Transplant. Proc. pmid:15350492
Yoshimi F et al. Canine total orthotopic small bowel transplantation under FK 506. 1991 Transplant. Proc. pmid:1721422
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Santiago SF et al. Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. 1991 Transplant. Proc. pmid:1721423
Sakimoto H et al. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation. 1996 Transplant. Proc. pmid:8658727
Collier DS et al. FK-506 in experimental renal allografts. 1987 Transplant. Proc. pmid:2445063
First International Workshop on FK-506. A potential breakthrough in immunosuppression. Proceedings. 1987 Transplant. Proc. pmid:2445066
Flechner SM Minimizing calcineurin inhibitor drugs in renal transplantation. 2003 Transplant. Proc. pmid:12742481
El-Sabrout R et al. Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. 2002 Transplant. Proc. pmid:12176638
Ji SM et al. Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. 2006 Transplant. Proc. pmid:17175303
Felipe CR et al. Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies. 2001 Feb-Mar Transplant. Proc. pmid:11267207
López-Vilella R et al. Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor. Transplant. Proc. pmid:25645789
Vanrenterghem Y Tacrolimus (FK 506) in kidney transplantation. 1998 Transplant. Proc. pmid:9723431
Gatti S et al. Graft-versus-host reaction and graft rejection after liver, small bowel or small bowel allotransplantation in the pig. 1998 Transplant. Proc. pmid:9745509
Aktas S et al. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. 2011 Transplant. Proc. pmid:21440732
Jelassi ML et al. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. 2011 Transplant. Proc. pmid:21440742
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Arikan C et al. Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy. 2003 Transplant. Proc. pmid:14697973
Takahara S et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. 1994 Transplant. Proc. pmid:7524219
Llull R et al. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. 1995 Transplant. Proc. pmid:7544504
Fujino Y et al. FK 506 treatment of experimental autoimmune uveoretinitis in primates. 1991 Transplant. Proc. pmid:1721454
Kanbay M et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. 2005 Transplant. Proc. pmid:16213325
Lo A et al. Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study. 2001 Feb-Mar Transplant. Proc. pmid:11267465
Burke GW et al. Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267467
Mita A et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. 2014 Transplant. Proc. pmid:24767351
Miki T et al. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. 1998 Transplant. Proc. pmid:9636444
Kobashigawa JA Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. 1998 Transplant. Proc. pmid:9636445
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Mehra MR et al. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. 2004 Transplant. Proc. pmid:15686716
Tamura S et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A single-center experience at the University of Tokyo. 2004 Transplant. Proc. pmid:15686738
Sakr MF et al. Protective effect of FK 506 against hepatic ischemia in rats. 1991 Transplant. Proc. pmid:1703689
Anglicheau D et al. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. 2007 Transplant. Proc. pmid:17889118